AvoMD, Operator of Clinical AI Platform, Secures $10 Million Series A Funding

AvoMD, the operator of the clinical AI platform 'Avo', announced on April 17, 2026, that it has secured a Series A investment of 10 million US dollars (approximately 15 billion won).

This Series A round was led by Noromoseley Partners, with participation from AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, Epsilon Health Investors, and Scrub Capital. Avo previously received early-stage investments from Dunamu & Partners in 2021 and 2023. Korean investors include Dunamu & Partners, Mirae Asset Capital, and FuturePlay.

원본보기 아이콘

AvoMD was founded in 2018 by CEO Park Junghum, an internal medicine specialist at a Harvard Medical School-affiliated hospital. The company provides an integrated clinical AI platform that supports every aspect of medical practice-including diagnosis, treatment planning, and documentation-based on electronic health records (EHRs). In particular, AvoMD has recently advanced its physician-only AI copilot services by incorporating large language models (LLMs) for AI-powered medical record writing (AI Scribe) and clinical consulting.

Currently, Avo is integrated with major global EHR systems such as Epic and athenahealth. Institutions that have adopted the platform have achieved tangible results, including reducing documentation time per patient by 35% and increasing annual billing revenue by 7.5 million US dollars.

Park Junghum, CEO of AvoMD, stated, "For AI to be truly helpful to medical professionals, patient data, clinical evidence, and insurance policies must be connected in a single workflow," adding, "Through Avo, we aim to become a core hub that transforms how clinicians deliver care."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.